Neos Kicks Off Global Indie Game Publishing Business
Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/
IndieTechGames
Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units.
The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units.
Through the sales and marketing of our in-house developed titles, we have had more opportunities to engage with games from around the world. At the same time, we have also increasingly encountered indie games that, for various reasons, have not been distributed globally.
In response, Neos has launched a new label, "IndieTech Games," to bring high-quality indie games—those that developers or rights holders are unable to publish themselves—to gamers worldwide. Leveraging our experience in game planning, development, and marketing, we will discover and showcase unique and captivating indie titles, distributing them globally in collaboration with our network of regional partners.
At "IndieTech Games," we carefully select titles that, like Neos' in-house developed games, place great importance on characters, art, and storytelling. Our goal is to create a publishing label that developers feel truly glad to work with.
At launch, we plan to release the following three titles. Details on pricing and release dates will be announced separately.
Title: PIGROMANCE
Genre: Action Puzzle
Developer/Licensor: GRAVITY (Korea)
Platform: Nintendo Switch
Rating: CERO C
Territory: Worldwide
Languages: Japanese, English, Korean, French, German, Spanish, Portuguese, Simplified Chinese, Traditional Chinese
Title: SEDAP! A Culinary Adventure
Genre: Action Adventure
Developer/Licensor: kopiforge (Singapore)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Taiwan, Hong Kong, Southeast Asia
Languages: Japanese, English, Korean, Indonesian, Filipino, Malay, Simplified Chinese, Traditional Chinese
Title: Sunsethills
Genre: Puzzle Adventure
Developer: Cotton Game (China)
Licensor: Asmik Ace (Japan)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Southeast Asia
Languages: Japanese, English, Korean, Simplified Chinese, Traditional Chinese
- Official X: https://x.com/indietech_games
- Official Instagram: https://www.instagram.com/indietech_games/
- Official Facebook: https://www.facebook.com/profile.php?id=61574205204129
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320035646/en/
Contacts
Neos Corporation
URL: https://www.neoscorp.jp -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neoscorp.j
p&esheet=54226979&newsitemid=20250320035646&lan=en-US&anchor=https%3A%2F%2Fwww.n
eoscorp.jp&index=4&md5=696cf8fe9cf4103145af1e75965b2057
Inquiries:info@neoscorp.jp
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom